Health breakthroughs and money matters, in plain words

Home » FDA Approval Moves Astellas’ Padcev Into Curative Bladder Cancer Setting

FDA Approval Moves Astellas’ Padcev Into Curative Bladder Cancer Setting

By

–

FDA Approval Moves Astellas' Padcev Into Curative Bladder Cancer Setting

The FDA approved durvalumab plus enfortumab vedotin-ejfv for muscle-invasive bladder cancer on November 14, 2026, based on the Phase III Volga trial, moving the antibody-drug conjugate Padcev into a curative-intent setting for the first time. The decision gives patients who cannot take or choose to decline cisplatin chemotherapy a new option before and after bladder-removal surgery.

Trial Design and Results

The global Volga trial (NCT04960709) enrolled 695 adults with resectable muscle-invasive bladder cancer (clinical stage T2–T4aN0/1M0 or T1N1M0) who were ineligible for or declined cisplatin-based chemotherapy. Patients were randomized 1:1:1 to three arms: a doublet arm receiving three 21-day cycles of neoadjuvant enfortumab vedotin plus durvalumab followed by radical cystectomy and up to nine 28-day cycles of adjuvant durvalumab; a triplet arm adding two cycles of tremelimumab before surgery and one after; and a control arm receiving radical cystectomy alone without neoadjuvant systemic therapy. The dual primary endpoints were event-free survival for each experimental arm versus control, with overall survival as a key secondary endpoint.

What This Means for Patients

For families facing a bladder cancer diagnosis, the approval shifts the conversation. Until now, enfortumab vedotin was approved only in metastatic settings. The Volga regimen — three cycles of combination therapy before surgery, then surgery, then up to nine cycles of durvalumab alone — offers a structured path for patients who previously had no standard systemic therapy before cystectomy if they could not tolerate cisplatin. Neeraj Agarwal, Co-Director of the Prostate Cancer Program at Dana-Farber Cancer Institute, noted the FDA approval on X and highlighted ongoing discussion comparing enfortumab vedotin plus pembrolizumab versus enfortumab vedotin plus durvalumab at the Uromigos live meeting, signaling that clinicians are already weighing how to position the new doublet against existing immunotherapy combinations.

Strategic Shift for the ADC Franchise

The approval marks a strategic inflection for Astellas Pharma. Formed in 2005 from the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, the Japanese company is a member of the Mitsubishi UFJ Financial Group keiretsu. Astellas acquired Seagen in 2024, gaining enfortumab vedotin (Padcev) as the cornerstone of its antibody-drug conjugate franchise. Moving Padcev from metastatic use into the perioperative, curative-intent space significantly expands the addressable population and revenue potential for the asset. Astellas executive Claus Zieler recently called for more coordinated EU drug access rules to compete with the United States and China for pharmaceutical investment, underscoring the commercial stakes of global adoption for new indications like this one.

Competitive Landscape and Market Access

The doublet regimen enters a field where pembrolizumab-based combinations have already established a foothold in bladder cancer. Agarwal’s public comparison of EV-plus-pembrolizumab versus EV-plus-durvalumab at the Uromigos meeting reflects the real-time clinical debate. Adoption will depend on how guidelines incorporate the Volga data, how payers evaluate the neoadjuvant-adjuvant sequence against existing standards, and whether the triplet arm — which added tremelimumab — shows a distinct benefit in longer follow-up. Astellas also continues to navigate geopolitical headwinds: an employee detained in China since March 2023 on espionage charges is expected to be released in mid-December 2026 after completing a three-and-a-half-year sentence.

Talk to your doctor or oncologist about whether this regimen is appropriate for your situation.

Sources

Photo: Piron Guillaume / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News